ENTA Enanta Pharmaceuticals Inc

Price (delayed)

$42

Market cap

$848.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.68

Enterprise value

$778.28M

Highlights
The debt has contracted by 14% YoY and by 10% from the previous quarter
Enanta Pharmaceuticals's revenue has decreased by 46% YoY and by 7% from the previous quarter
The gross profit has contracted by 46% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of ENTA
Market
Shares outstanding
20.2M
Market cap
$848.2M
Enterprise value
$778.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.94
Price to sales (P/S)
9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.27
Earnings
Revenue
$94.16M
EBIT
-$80.82M
EBITDA
-$77.29M
Free cash flow
-$40.34M
Per share
EPS
-$3.68
Free cash flow per share
-$2
Book value per share
$21.62
Revenue per share
$4.67
TBVPS
$23.19
Balance sheet
Total assets
$467.77M
Total liabilities
$31.74M
Debt
$7.82M
Equity
$436.03M
Working capital
$401.6M
Liquidity
Debt to equity
0.02
Current ratio
16.09
Quick ratio
14.9
Net debt/EBITDA
0.9
Margins
EBITDA margin
-82.1%
Gross margin
100%
Net margin
-78.6%
Operating margin
-89.9%
Efficiency
Return on assets
-15.2%
Return on equity
-16.2%
Return on invested capital
-20.7%
Return on capital employed
-18.3%
Return on sales
-85.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENTA stock price

How has the Enanta Pharmaceuticals stock price performed over time
Intraday
2.39%
1 week
0.45%
1 month
-12.17%
1 year
-13.97%
YTD
-0.24%
QTD
-4.57%

Financial performance

How have Enanta Pharmaceuticals's revenue and profit performed over time
Revenue
$94.16M
Gross profit
$94.16M
Operating income
-$84.63M
Net income
-$73.98M
Gross margin
100%
Net margin
-78.6%
Enanta Pharmaceuticals's revenue has decreased by 46% YoY and by 7% from the previous quarter
The gross profit has contracted by 46% YoY and by 7% from the previous quarter
The net margin has contracted by 38% from the previous quarter
The operating margin has contracted by 37% from the previous quarter

Growth

What is Enanta Pharmaceuticals's growth rate over time

Valuation

What is Enanta Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.94
P/S
9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.27
The EPS has declined by 27% since the previous quarter
ENTA's P/B is 35% below its 5-year quarterly average of 3.0 and 8% below its last 4 quarters average of 2.1
The equity has decreased by 10% YoY and by 3.5% from the previous quarter
Enanta Pharmaceuticals's revenue has decreased by 46% YoY and by 7% from the previous quarter
The price to sales (P/S) is 8% higher than the last 4 quarters average of 8.3 and 3.4% higher than the 5-year quarterly average of 8.7

Efficiency

How efficient is Enanta Pharmaceuticals business performance
The return on sales has declined by 42% since the previous quarter
ENTA's return on invested capital is down by 36% since the previous quarter
Enanta Pharmaceuticals's ROA has decreased by 31% from the previous quarter
Enanta Pharmaceuticals's return on equity has decreased by 31% QoQ

Dividends

What is ENTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTA.

Financial health

How did Enanta Pharmaceuticals financials performed over time
Enanta Pharmaceuticals's quick ratio has decreased by 24% YoY and by 18% QoQ
Enanta Pharmaceuticals's current ratio has decreased by 22% YoY and by 17% from the previous quarter
The debt is 98% less than the equity
The debt has contracted by 14% YoY and by 10% from the previous quarter
The equity has decreased by 10% YoY and by 3.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.